Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1875 - Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database


09 Oct 2016


Poster display


Aristotelis Bamias


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


A. Bamias1, K. Tzannis1, M. Liontos2, L. Harshman3, S.J. Crabb4, Y. Wong5, S.K. Pal6, T.B. Powles7, J. Bellmunt8, U. De Giorgi9, S. Ladoire10, N. Agarwal11, E.Y. Yu12, G. Niegisch13, C.N. Sternberg14, A. Alva15, S. Srinivas16, J. Rosenberg17, R. Investigators18

Author affiliations

  • 1 Clinical Therapeutics, National and Kapodistrian University of Athens, 115 28 - Athens/GR
  • 2 Oncology Unit, Department Of Clinical Therapeutics, Alexandra Hospital, 115 28 - Athens/GR
  • 3 Medical Oncology, Dana-Farber Cancer Institute, Boston/US
  • 4 Medical Oncology, University of Southampton, Southampton/GB
  • 5 Medical Oncology, Fox Chase Cancer Center, Philadelphia/US
  • 6 Medical Oncology And Experimental Therapuetics, City of Hope, 91010 - Duarte/US
  • 7 Department Of Medical Oncology, St. Bartholomew's Hospital, EC1A 7BE - London/GB
  • 8 Oncology, Dana-Farber Cancer Institute, Boston, MA/US
  • 9 Medical Oncology, Istituto Tumori della Romagna I.R.S.T., Meldola/IT
  • 10 Medical Oncology, Centre Georges-François Leclerc (Dijon), Dijon/FR
  • 11 Medical Oncology, Huntsman Cancer Institute, Salt Lake City/US
  • 12 Medical Oncology, Univ. Washington/VAPSHCS, Seattle/US
  • 13 Medical Oncology, Univesitätsklinikum Düsseldorf, Düsseldorf/DE
  • 14 Medical Oncology, Azienda Ospedaliera S. Camillo Forlanini, Roma/IT
  • 15 Medical Oncology, University of Michigan, East Lansing/US
  • 16 Medical Oncology, Stanford University, Palo Alto/US
  • 17 Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 18 Oncology, Mount SInai Medical College, New York/US


Abstract 1875


Cisplatin-based chemotherapy is the treatment of choice in mUC. A significant proportion of patients do not receive chemotherapy, while about 50% of treated patients do not receive cisplatin. We used the multinational RISC database to map patterns of chemotherapy utilization and adherence to recently published UFC criteria (Galsky, 2011) in unselected mUC patients


Selection criteria: diagnosis of mUC, transitional-cell, mixed, squamous and adeno histologies.


Of 1974 mUC patients 475 (25%) did not receive 1st-line chemotherapy. No chemotherapy administration was associated with: non-pure TCC histology, higher Charslon Comorbidity Index (CCI), non-caucasian race, non-european country, low volume center (contribution of


Patterns of practice are influenced by various factors, such as age, co-morbidities, race, country of origin and volume of mUC patients. 25% of non-cisplatin treated patients were fit-for-cisplatin. Age and co-morbidities represent major factors, which lead to deviation from the established UFC criteria.

Clinical trial identification

Legal entity responsible for the study



Icahn School of Medicine, Mount Sinai USA


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings